Molecular Pharmacology Fast Forward. Published on April 7, 2009 as doi: 10.1124/mol.109.056127
This article has not been copyedited and formatted. The final version may differ from this version.

Increased $GABA_B$ Receptor-mediated Signaling Reduces the Susceptibility of Fragile X Knockout Mice to Audiogenic Seizures

By

Laura K.K. Pacey, Scott P. Heximer, and David R. Hampson*

From the Leslie Dan Faculty of Pharmacy (L.K.K.P., D.R.H.) and Departments Pharmacology (D.R.H.) and Physiology (S.P.H.), Faculty of Medicine University of Toronto

Molecular Pharmacology Fast Forward. Published on April 7, 2009 as DOI: 10.1124/mol.109.056127
This article has not been copyedited and formatted. The final version may differ from this version.

Running title: $GABA_B$ Receptor-mediated Signaling in Fragile X Syndrome

Corresponding author:
Dr. David R. Hampson
Leslie Dan Faculty of Pharmacy
University of Toronto
144 College St. Toronto, Ontario, Canada M5S 3M2
(p) 416-978-4494 (f) 416-978-8511
d.hampson@utoronto.ca

Number of pages of text: 23

Number of Tables: 0

Number of figures: 6

Number of references: 44

Number of words in Abstract: 193
Number of words in Introduction: 605
Number of words in Discussion: 809

Abbreviations:
FMRP, fragile X mental retardation protein; GPCR, G-protein coupled receptors; K_{IRs}, inward rectifying potassium channels; mGluR, metabotropic glutamate receptor

Molecular Pharmacology Fast Forward. Published on April 7, 2009 as DOI: 10.1124/mol.109.056127
This article has not been copyedited and formatted. The final version may differ from this version.

Abstract

Mice lacking the gene encoding fragile X mental retardation protein (FMR1) are susceptible to audiogenic seizures and antagonists of the Group I metabotropic glutamate receptors (mGluRs) have been shown to block seizures in FMR1 knockout mice. We investigated whether the G-protein inhibitory activity of the regulator of G-protein signaling protein, RGS4, could also alter the susceptibility to audiogenic seizures in FMR1 mice. Surprisingly, male FMR1/RGS4 double knockout mice showed reduced susceptibility to audiogenic seizures compared to age-matched FMR1 mice. These data raised the intriguing possibility that loss of RGS4 increased signaling through another G-protein pathway that reduces seizure susceptibility in FMR1 mice. Indeed, administration of the $GABA_B$ receptor agonist baclofen to FMR1 mice inhibited seizures, while the $GABA_B$ receptor antagonist CGP 46381 increased seizure incidence in double knockout mice but not in wild-type mice. Lastly, audiogenic seizures could be induced in wild-type mice by co-administering CGP 46381 and the mGluR5 positive allosteric modulator CDPPB. These data show for the first time that $GABA_B$ receptor-mediated signaling antagonizes the seizure-promoting effects of the mGluRs in FMR1 knockout mice and point to the potential therapeutic benefit of $GABA_B$ agonists for the treatment of fragile X syndrome.

Molecular Pharmacology Fast Forward. Published on April 7, 2009 as DOI: 10.1124/mol.109.056127
This article has not been copyedited and formatted. The final version may differ from this version.

Introduction

Fragile X syndrome results from a mutation in the X-linked FMR1 gene leading to the absence of the gene product fragile X mental retardation protein (FMRP). Individuals with fragile X exhibit a spectrum of abnormalities including mild to moderate mental retardation, impaired learning and memory, hyperactivity, and anxiety (O'donnell and Warren, 2002; Bagni and Greenough, 2005). Autistic-like behaviours and seizures are present in about 20 percent of individuals (Wisniewski et al., 1991; Bailey, Jr. et al., 2008). The metabotropic glutamate receptor (mGluR) theory of fragile X posits that FMRP regulates the translation of specific mRNAs expressed in response to Group I mGluR activation. In the absence of FMRP, group I mGluR signaling is enhanced, leading to several neurological alterations associated with fragile X syndrome (Bear et al., 2004). Recent evidence indicates that perturbations in cellular signaling in fragile X extends to GABA-gated anion channels (Centonze et al., 2008; Chang et al., 2008; Curia et al., 2008) and to other non-mGluR GPCRs including dopamine receptors and muscarinic acetylcholine receptors (Volk et al., 2007; Wang et al., 2008).

The FMR1 knockout mouse exhibits many characteristics that mimic fragile X in humans and is widely used to study fragile X syndrome. One of the most robust and reproducible phenotypes in the FMR1 knockout mouse is susceptibility to audiogenic seizures (Musumeci et al., 2000; Chen and Toth, 2001; Yan et al., 2004; Yan et al., 2005; Musumeci et al., 2007; Dolen et al., 2007). GPCRs including the Group I mGluR, mGluR5 (Yan et al., 2005; Dolen et al., 2007) and $GABA_B$ receptors (Faingold, 2002) have been implicated in the development of audiogenic seizures in rats and mice and the mGluR5 antagonist MPEP has been shown to reduce seizures in FMR1 mice (Yan et al.,

Molecular Pharmacology Fast Forward. Published on April 7, 2009 as DOI: 10.1124/mol.109.056127
This article has not been copyedited and formatted. The final version may differ from this version.

2005), and to reduce the dendritic spine abnormalities in cultured neurons from FMR1 mice (de Vrij et al., 2008).

Regulator of G-protein signaling (RGS) proteins are GTPase-activating proteins for heterotrimeric G-protein α subunits that can modulate GPCR signaling (Abramow-Newerly et al., 2006; Blazer and Neubig, 2009). RGS proteins are important regulators of GPCR signaling and alterations in RGS protein expression have been suggested to play a role in a number of disease states (Muma et al., 2003; Riddle et al., 2005; Liu et al., 2006). RGS4 has been shown to be a potent inhibitor of both Gq- and Gi/o-coupled pathways; however, the specific GPCR pathways that it regulates *in vivo* are not known. RGS4 is highly expressed in the developing and adult brain (Nomoto et al., 1997; Ingi and Aoki, 2002) where it inhibits signaling of Group I mGluRs (Saugstad et al., 1998). More recently, RGS4 has been shown to associate with $GABA_B$ receptors and inward rectifying K^+ channels (K_{IR}) (Fowler et al., 2007), suggesting it may also regulate $GABA_B$ mediated signaling. In the FMR1 knockout mouse, RGS4 mRNA was shown to be decreased in hippocampus and cortex during early postnatal development (Tervonen et al., 2005), indicating a possible role for RGS4 in the pathogenesis of Fragile X Syndrome.

The objective of the present study was to examine the role of RGS4 in fragile X syndrome. We crossed FMR1 knockout mice with RGS4 knockout mice to produce FMR1/RGS4 double knockouts. Since removing RGS4 may be expected to enhance mGluR signaling, we anticipated observing exacerbated symptoms of fragile X in double knockout mice. Instead, we demonstrate that the absence of RGS4 expression rescues audiogenic seizure susceptibility in FMR1 knockout mice and that this effect is partly

Molecular Pharmacology Fast Forward. Published on April 7, 2009 as DOI: 10.1124/mol.109.056127
This article has not been copyedited and formatted. The final version may differ from this version.

mediated by increased signaling through $GABA_B$ receptors. These findings suggest that audiogenic seizures in FMR1 knockout mice may be caused by an imbalance in mGluR and GABA mediated signaling.

Materials and Methods

Animals

All animal experiments were carried out in accordance with the guidelines set out by the Canadian Council on Animal Care and were approved by the University of Toronto Animal Care Committee. The *Rgs4*^{tm1Dgen}/J knockout mouse strain (described in Cifelli et al., 2008) was backcrossed seven generations onto the C57Bl/6 background. FMR1 knockout mice on the C57/Bl6 background were generously provided by Dr. William Greenough, University of Illinois, and bred at the University of Toronto. FMR1/RGS4 double knockout mice were created by breeding RGS4 knockout males with FMR1 knockout females. The resultant female (FMR1 heterozygote; RGS4 heterozygote) and male (FMR1 knockout; RGS4 heterozygote) offspring were crossed and some F2 generation offspring were used for seizure experiments. FMR1/RGS4 double knockout offspring of the F2 generation were mated to produce pure double knockout lines.

Genotyping

FMR1 genotyping was based on the presence or absence of the wild-type or knockout FMR1 allele, as previously described (Dolen et al., 2007). For the wild-type allele, primers S1 (5’ GTG GTT AGC TAA AGT GAG GAT GAT 3’) and S2 (5’ CAG

Molecular Pharmacology Fast Forward. Published on April 7, 2009 as DOI: 10.1124/mol.109.056127
This article has not been copyedited and formatted. The final version may differ from this version.

GTT TGT TGG GAT TAA CAG ATC 3') were used. For the FMR1 knockout allele, primers M2 (5' ATC TAG TCA TGC TAT GGA TAT CAG C 3') and N2 (5' GTG GGC TCT ATG GCT TCT GAG G 3') were used. The following PCR conditions were used: 95^{o}C for 5 min; 34 PCR cycles of 30 sec at 95^{o}C, 30 sec at 61^{o}C, and 1 min at 72^{o}C; 10 min at 72^{o}C. Wild-type and mutant mouse PCR reactions were run separately. The reaction products were combined and separated on a 1.5% agarose gel. The wild-type and knockout alleles produced bands of 528bp and 800bp respectively.

Screening for the RGS4 gene was based on the presence or absence of the wild-type or knockout alleles. For the wild-type allele, GSET (5' CCA TCT TGA CCC AAA TCT GGC TCA G 3') and GSE1 (5' GGA CAT GAA ACA TCG GCT GGG GTT C 3') were used. For the knockout allele, GSET and NeoT (5' GGG CCA GCT CAT TCC TCC CAC TCA T 3') were used. The following PCR program was used: 5 min at 95^{o}C; 34 PCR cycles of 30 sec at 95^{o}C, 30 sec at 70^{o}C, and 1 min at 72^{o}C; 10 min at 72^{o}C. Wild-type and knockout PCR reactions were run separately. The wild-type and knockout alleles produced bands of 226bp and 484bp respectively.

RT-PCR

Total RNA was isolated from mouse forebrain using the RNeasy kit (Qiagen) following the manufacturer's protocol. Two micrograms of total RNA was reverse transcribed with random nonomers (Sigma) using the Superscript II Reverse Transcriptase (Invitrogen) as described by the manufacturer. PCR was performed using RGS4 cDNA-specific forward (5' GCC AAG AAG AAG TCA AGA AAT GGG C 3') and reverse (5' TGG CTC CTT TCT GCT TCT CTG CC 3') primers. The following

Molecular Pharmacology Fast Forward. Published on April 7, 2009 as DOI: 10.1124/mol.109.056127
This article has not been copyedited and formatted. The final version may differ from this version.

PCR reaction was run: 95^{o}C for 10 min; 30 PCR cycles of 95^{o}C for 30 sec, 60^{o}C for 30 sec, and 72^{o}C for 2 min. The reaction products were separated on a 1.5% agarose gel. The presence of the RGS4 cDNA was indicated by a 420bp band.

Western Blotting

Adult wild-type, FMR1 knockout and FMR1/RGS4 double knockout mice were euthanized with an overdose of ketamine/xylazine and the brains were removed and placed on ice. One half the forebrain was homogenized in ice cold 50mM Tris, 1% SDS, pH 7.4 supplemented with protease inhibitor cocktail (Sigma) using a glass/teflon homogenizer. The protein concentration was determined using the BCA assay (Sigma). Twenty micrograms of protein per sample were loaded onto a 10% polyacrylamide-SDS gel and transferred onto a nitrocellulose membrane after electrophoresis. The membranes were blocked in 5% milk overnight and probed with the 2F5-1 anti-FMRP antibody (1:1000; gift of Jennifer Darnell, The Rockefeller University) and a donkey anti-mouse HRP-conjugated secondary antibody (Jackson Labs). The immunoreactive proteins were visualized using the FluorChem^{TM} MultiImage Light Cabinet (Alpha Innotech).

Audiogenic seizure testing and drug injections

For audiogenic seizure testing, the apparatus consisted of a plexiglass mouse cage (28x17x14 cm) with a 135dB sound source (Piezo siren, Electrosonic model XL-5530LW300-S-R P.V.I.) attached to the lid and extending 5cm down into the cage. Mice (27-30 days) were placed individually into the testing apparatus and were allowed to explore for 2 minutes, after which the bell was rung for 2 minutes. Seizure activity was

Molecular Pharmacology Fast Forward. Published on April 7, 2009 as DOI: 10.1124/mol.109.056127
This article has not been copyedited and formatted. The final version may differ from this version.

observed and scored using a seizure severity score as follows: Wild running = 1; clonic seizure = 2; tonic seizure = 3; status epilepticus/respiratory arrest/death = 4 (Musumeci et al., 2000). Animals were considered to have had a seizure if the seizure severity score was greater than 1. Animals were tested only once. Seizure testing was carried out between 1:00 p.m. and 6:00 p.m.

For drug injection studies, an intraperitoneal injection (i.p.) of drug or vehicle (0.1mL/10g body weight) was administered 30 or 45 minutes prior to seizure testing. The drug doses and vehicles are as follows: 2.0 mg/kg R-baclofen (Research Biochemicals International) in saline; 60 mg/kg CPG 46381 (3-Aminopropyl) (cyclohexylmethyl) phosphinic acid; Tocris Bioscience) in saline; 2.5 mg/kg CDPPB (3-Cyano-N-(1,2 diphenyl-1H-pyrazol-5-yl) benzamide; Tocris Bioscience) in 50% DMSO, 50% sterile saline. Fisher's Exact test was used for statistical analysis of seizure susceptibility data.

Results

FMR1/RGS4 double knockout mice do not express FMRP or RGS4

FMR1/RGS4 double knockout mice were created by crossing female FMR1 knockout and male RGS4 knockout mice. The resulting offspring were mated and the F2 generation genotyped for FMR1 and RGS4 (Figure 1A and B). FMR1/RGS4 double knockouts from the F2 generation were subsequently mated to produce pure double knockout lines. Western blots of adult forebrain tissue demonstrated the absence of FMRP expression in FMR1/RGS4 double KO mice (Figure 1C). Because RGS4 protein is difficult to detect on western blots, RT-PCR was used to probe for RGS4 mRNA

Molecular Pharmacology Fast Forward. Published on April 7, 2009 as DOI: 10.1124/mol.109.056127
This article has not been copyedited and formatted. The final version may differ from this version.

expression. FMR1/RGS4 double knockout mice did not express RGS4 mRNA (Figure 1D). These results verify that the double knockout mice did not express FMRP or RGS4.

RGS4 knockout rescues audiogenic seizures in FMR1 knockout mice

Postnatal day 27-30 mice were exposed to a 135db alarm for 2 minutes and seizure susceptibility was evaluated as previously described (Musumeci et al., 2000). In total, 53% of FMR1 knockout mice exhibited sound-induced seizures, compared to 4% of wild-type animals (Figure 2A, $p < 0.001$). FMR1/RGS4 double knockout mice displayed a 71% reduction in seizure incidence compared to FMR1 knockout mice ($p < 0.01$). The incidence of seizures in FMR1/RGS4 double knockout mice was not statistically different from that of wild-type animals ($p > 0.05$). Interestingly, we also observed a trend towards decreased seizure susceptibility in male FMR1 knockout mice heterozygous for RGS4 (Figure 2A, $p = 0.07$).

Since FMR1 is an X-linked gene and the possible genotype combinations differ based on sex, we also analyzed the seizure data separately for males and females (Figure 2B and C respectively). Male FMR1/RGS4 double knockout mice displayed a significant 88% reduction in seizure incidence compared to the male FMR1 mice (Figure 2B, $p < 0.01$). The incidence of seizures was reduced by 46% in female FMR1/RGS4 double knockouts compared to female FMR1 mice, although this difference did not reach statistical significance (Figure 2C, $p > 0.05$). The reason for this differential effect is unclear but may be accounted for by hormonal differences in female vs. male mice, or differences attributed to the hemizygous (XY) vs. homozygous (XX) genotype. To our

Molecular Pharmacology Fast Forward. Published on April 7, 2009 as DOI: 10.1124/mol.109.056127
This article has not been copyedited and formatted. The final version may differ from this version.

knowledge there is no evidence to suggest sex differences in RGS4 expression or function, but further study is needed to more closely examine this issue.

RGS4 heterozygous and RGS4 knockout males (Figure 2B; WT/Het and WT/KO respectively) and RGS4 knockout females (Figure 2C; WT/KO) did not exhibit seizures. FMR1 heterozygous females (Figure 2C; Het/WT, Het/Het and Het/KO) showed some seizure activity, irrespective of their RGS4 genotype, but this was not significantly different from wild-type levels. Together, these results demonstrate that ablating one or both copies of the RGS4 gene reduces seizure susceptibility in fragile X knockout mice.

The $GABA_B$ agonist baclofen reduces audiogenic seizures in FMR1 KO mice

To test for a role of $GABA_B$ receptors in audiogenic seizure susceptibility, 27-30 day old FMR1 knockout mice (19 males and 31 females) were treated with the $GABA_B$ agonist R-baclofen (1.0 or 2.0 mg/kg i.p.) administered 45 minutes before seizure testing. Treatment with 1.0 and 2.0 mg/kg R-baclofen produced a 67% ($p < 0.05$) and 79% ($p < 0.01$) decrease respectively in seizure incidence (Figure 3) compared to vehicle controls. When analyzed separately, both male and female FMR1 knockout mice showed statistically significant decreases ($p < 0.05$) in seizure activity at both doses (data not shown). These results demonstrate that stimulating $GABA_B$ mediated signaling rescues seizures in FMR1 knockout mice.

Treatment with a $GABA_B$ antagonist induces seizures in FMR1/RGS4 double knockout mice but not in wild-type mice

Molecular Pharmacology Fast Forward. Published on April 7, 2009 as DOI: 10.1124/mol.109.056127
This article has not been copyedited and formatted. The final version may differ from this version.

Having demonstrated an anti-convulsant effect of the $GABA_B$ agonist baclofen on audiogenic seizures in FMR1 knockout mice, we sought to determine whether decreasing $GABA_B$ receptor mediated signaling could induce seizures in wild-type mice. At 27-30 days of age, male wild-type mice were given an i.p. injection of the $GABA_B$ antagonist CGP 46381 (60 mg/kg) 45 minutes before seizure testing. This treatment did not induce audiogenic seizures in wild-type or RGS4 knockout mice (Figure 4). Although the dose of CGP 46381 used was approximately 10-fold higher than the IC_{50} of this drug (Olpe et al., 1993), it is conceivable that a higher dose of CGP 46381 could have reduced seizure incidence. Nevertheless, this result indicates that reducing $GABA_B$ -mediated signaling alone is insufficient to induce seizures in wild-type mice. However, when the same 60 mg/kg dose of CGP 46381 was tested on FMR1/RGS4 double knockout mice, seizures were observed in 86% of double knockout males ($p < 0.05$); this represented approximately a 5-fold increase in seizure incidence over vehicle controls (Figure 4). This finding suggests that genetically eliminating expression of RGS4 rescues the audiogenic seizure phenotype in FMR1 knockout mice by increasing signaling through $GABA_B$ receptors.

Co-administration of a $GABA_B$ antagonist and an mGluR5 positive allosteric modulator induces audiogenic seizures in wild-type mice

We hypothesize that the $GABA_B$ antagonist CGP 46381 can induce seizures in FMR1/RGS4 double knockout mice because they already have increased mGluR signaling compared to wild-type mice. To test whether increased mGluR signaling, coupled with reduced $GABA_B$ receptor mediated signaling could induce seizures in wild-

type mice, male wild-type mice were administered CGP 46381 together with the mGluR5 positive allosteric modulator CDPPB at doses which did not induce seizures when administered alone. At high doses (above 10 mg/kg) CDPPB induced seizure activity in 27-30 day old wild-type mice (result not shown). However, a dose of 2.5 mg/kg CDPPB administered i.p. 30 minutes before testing did not induce seizure activity in these animals (Figure 5). Similarly, a 60 mg/kg dose of CGP 46381 administered i.p. 30 minutes before testing did not elicit seizures in wild-type mice (Figure 5). However, when 2.5 mg/kg CDPPB was administered in combination with 60 mg/kg CGP 46381, 75% of wild-type mice exhibited seizure activity (Figure 5). This result provides additional evidence that an imbalance between Group I mGluR and $GABA_B$ receptor signaling promotes seizures.

Discussion

We evaluated audiogenic seizure susceptibility, a well established phenotype of FMR1 knockout mice (Musumeci et al., 2000; Yan et al., 2004). Since RGS4 over-expression can attenuate signaling through mGluR5 (Saugstad et al., 1998), we postulated FMR1/RGS4 double knockout mice may show increased seizures as compared to FMR1 single knockouts. Instead, a dramatic reduction in audiogenic seizures was observed in the double knockout mice. This result suggested that in addition to mGluRs, other GPCR-dependent mechanisms may regulate the sensitivity of FMR1 mice to audiogenic seizures.

The complete list of specific pathways regulated by RGS4 *in vivo* is not known; however, our recent work shows that Gi/o-coupled signaling to inward rectifying

Molecular Pharmacology Fast Forward. Published on April 7, 2009 as DOI: 10.1124/mol.109.056127
This article has not been copyedited and formatted. The final version may differ from this version.

potassium channels (K_{IRs}) is markedly increased in the hearts of rgs4-null mice (Cifelli et al., 2008). It is possible that enhanced signaling through an analogous pathway in neurons, (i.e. $GABA_B$ receptor activation of K_{IRs}) may explain the observed decrease in susceptibility to audiogenic seizures. Indeed, alterations in GABA-mediated signaling have been shown to influence the development of audiogenic seizures (Caspary et al., 1984; Faingold et al., 1994). In support of a role for a protective effect of GABA signaling in the prevention of fragile X seizures, we observed reduced seizures in FMR1 knockout mice after treatment with the $GABA_B$ receptor agonist R-baclofen. $GABA_B$ receptors are Gαi/o-coupled receptors; activation of $GABA_B$ receptors leads to reduced cAMP production and stimulates opening of K_{IRs}, leading to hyperpolarization and increased membrane potential (Jacobson et al., 2007; Labouebe et al., 2007; Ulrich and Bettler, 2007). Mounting evidence suggests that, in addition to its GAP activity, RGS4 may be selectively targeted to different GPCR-K_{IR} signaling complexes in different cell types (Jaen and Doupnik, 2006). RGS4 has been shown to interact with $GABA_B$ receptors and K_{IR} channels (Fowler et al., 2007) suggesting the possibility that $GABA_B$ receptors are regulated by RGS4.

In the thalamus, mGluR activation enhances, while $GABA_B$ receptor activation suppresses, auditory signals necessary for sound detection (Schwarz et al., 2000). Several brain regions implicated in the development and progression of auditory seizures in rodents, including the cochlea, inferior and superior colliculus, and periaqueductal grey, express mGluR5, $GABA_B$ receptors, and/or RGS4 (Romano et al., 1995; Gold et al., 1997; Margeta-Mitrovic et al., 1999; Ross and Coleman, 2000; Friedland et al., 2006; Maison et al., 2009). We propose that in the auditory pathways involved in seizure

Molecular Pharmacology Fast Forward. Published on April 7, 2009 as DOI: 10.1124/mol.109.056127
This article has not been copyedited and formatted. The final version may differ from this version.

induction and progression, auditory signals are balanced by mGluR (activating) and $GABA_B$ receptor (suppressing) signaling (Figure 6). In wild-type animals, a balance between mGluR and $GABA_B$ receptor signaling is maintained and loud sounds do not induce seizure activity. However, in FMR1 knockout mice, enhanced signaling through mGluRs may disrupt this balance resulting in seizures. Consistent with this hypothesis, decreasing signaling through Group I mGluRs (Yan et al., 2005; Dolen et al., 2007) or increasing signaling through $GABA_B$ receptors (this study) rescues audiogenic seizures in FMR1 knockout mice.

If audiogenic seizures result from an imbalance in mGluR and $GABA_B$ mediated signaling, we envisaged that seizures might be induced in wild-type mice by disrupting this balance pharmacologically. Although treating wild-type mice with the $GABA_B$ antagonist CGP 46381 did not induce seizures, the same dose of CGP 46381 elicited a high incidence of seizures in FMR1/RGS4 double knockout mice. We hypothesize that, in wild-type mice, RGS4 regulates signaling through $GABA_B$ receptors. In FMR1/RGS4 double knockout mice, mGluR signaling is enhanced due to the absence of FMRP. However, the loss of RGS4 regulation would be expected to increase inhibitory signaling through $GABA_B$ receptors, which would restore the auditory signaling balance and prevent seizures. This hypothesis presumes, at least in the context of seizures, a greater effect of RGS4 on $GABA_B$ signaling than mGluR-mediated signaling. Consistent with this idea, treating double knockout mice with a $GABA_B$ antagonist reversed the protective effect and induced seizures, and additionally, seizures could be induced in wild-type mice by treatment with an mGluR5 positive allosteric modulator together with a $GABA_B$ antagonist at doses that, when administered alone, did not elicit seizures.

Molecular Pharmacology Fast Forward. Published on April 7, 2009 as DOI: 10.1124/mol.109.056127
This article has not been copyedited and formatted. The final version may differ from this version.

Together, these results provide evidence that audiogenic seizures result from an imbalance in mGluR and $GABA_B$ receptor signaling.

Given the role of RGS4 in regulating GPCR signaling, which is altered in fragile X, it is possible that genetic elimination of RGS4 may also reverse other fragile X phenotypes. RGS4 knockout mice show a relatively mild phenotype which includes sensorimotor deficits (Grillet et al., 2005) and cardiac abnormalities resulting from enhanced parasympathetic signaling (Cifelli et al., 2008). Expression of RGS4 mRNA has previously been reported to be decreased in the brains of FMR1 mice (Tervonen et al., 2005). Based on our findings, it is possible that this decrease is a compensatory response to increased mGluR signaling rather than a causative factor in the pathogenesis of fragile X. Although further study is needed to more precisely determine the role of RGS4 in fragile X, collectively these observations indicate that RGS4 could be a potential target for treating fragile X syndrome.

Acknowledgements. The authors wish to thank Dr. W.T Greenough (University of Illinois) for providing the FMR1 knockout mice, Dr. J. Darnell (The Rockefeller University) for the 2F5-1 FMRP antibody, and Mr. Carlo Cifelli for maintaining the RGS4 mouse colony.

References

Abramow-Newerly M, Roy AA, Nunn C and Chidiac P (2006) RGS proteins have a signalling complex: interactions between RGS proteins and GPCRs, effectors, and auxiliary proteins. *Cell Signal* **18**:579-591.

Bagni C and Greenough WT (2005) From mRNP trafficking to spine dysmorphogenesis: the roots of fragile X syndrome. *Nat Rev Neurosci* **6**:376-387.

Bailey DB, Jr., Raspa M, Olmsted M and Holiday DB (2008) Co-occurring conditions associated with FMR1 gene variations: findings from a national parent survey. *Am J Med Genet A* **146A**:2060-2069.

Bear MF, Huber KM and Warren ST (2004) The mGluR theory of fragile X mental retardation. *Trends Neurosci* **27**:370-377.

Blazer LL and Neubig RR (2009) Small molecule protein-protein interaction inhibitors as CNS therapeutic agents: current progress and future hurdles. *Neuropsychopharmacology* **34**:126-141.

Caspary DM, Rybak LP and Faingold CL (1984) Baclofen reduces tone-evoked activity of cochlear nucleus neurons. *Hear Res* **13**:113-122.

Centonze D, Rossi S, Mercaldo V, Napoli I, Ciotti MT, De C, V, Musella A, Prosperetti C, Calabresi P, Bernardi G and Bagni C (2008) Abnormal striatal GABA transmission in the mouse model for the fragile X syndrome. *Biol Psychiatry* **63**:963-973.

Chang S, Bray SM, Li Z, Zarnescu DC, He C, Jin P and Warren ST (2008) Identification of small molecules rescuing fragile X syndrome phenotypes in Drosophila. *Nat Chem Biol* **4**:256-263.

Chen L and Toth M (2001) Fragile X mice develop sensory hyperreactivity to auditory stimuli. *Neuroscience* **103**:1043-1050.

Cifelli C, Rose RA, Zhang H, Voigtlaender-Bolz J, Bolz SS, Backx PH and Heximer SP (2008) RGS4 regulates parasympathetic signaling and heart rate control in the sinoatrial node. *Circ Res* **103**:527-535.

Curia G, Papouin T, Seguela P and Avoli M (2008) Downregulation of tonic GABAergic Inhibition in a Mouse Model of Fragile X Syndrome. *Cereb Cortex*.

de Vrij FM, Levenga J, van der Linde HC, Koekkoek SK, De Zeeuw CI, Nelson DL, Oostra BA and Willemsen R (2008) Rescue of behavioral phenotype and neuronal protrusion morphology in Fmr1 KO mice. *Neurobiol Dis* **31**:127-132.

Dolen G, Osterweil E, Rao BS, Smith GB, Auerbach BD, Chattarji S and Bear MF (2007) Correction of fragile X syndrome in mice. *Neuron* **56**:955-962.

Faingold CL (2002) Role of GABA abnormalities in the inferior colliculus pathophysiology - audiogenic seizures. *Hear Res* **168**:223-237.

Faingold CL, Marcinczyk MJ, Casebeer DJ, Randall ME, Arneric SP and Browning RA (1994) GABA in the inferior colliculus plays a critical role in control of audiogenic seizures. *Brain Res* **640**:40-47.

Fowler CE, Aryal P, Suen KF and Slesinger PA (2007) Evidence for association of GABA(B) receptors with Kir3 channels and regulators of G protein signalling (RGS4) proteins. *J Physiol* **580**:51-65.

Friedland DR, Popper P, Eernisse R and Cioffi JA (2006) Differentially expressed genes in the rat cochlear nucleus. *Neuroscience* **142**:753-768.

Gold SJ, Ni YG, Dohlman HG and Nestler EJ (1997) Regulators of G-protein signaling (RGS) proteins: region-specific expression of nine subtypes in rat brain. *J Neurosci* **17**:8024-8037.

Grillet N, Pattyn A, Contet C, Kieffer BL, Goridis C and Brunet JF (2005) Generation and characterization of Rgs4 mutant mice. *Mol Cell Biol* **25**:4221-4228.

Ingi T and Aoki Y (2002) Expression of RGS2, RGS4 and RGS7 in the developing postnatal brain. *Eur J Neurosci* **15**:929-936.

Jacobson LH, Kelly PH, Bettler B, Kaupmann K and Cryan JF (2007) Specific roles of GABA(B(1)) receptor isoforms in cognition. *Behav Brain Res* **181**:158-162.

Jaen C and Doupnik CA (2006) RGS3 and RGS4 differentially associate with G protein-coupled receptor-Kir3 channel signaling complexes revealing two modes of RGS modulation. Precoupling and collision coupling. *J Biol Chem* **281**:34549-34560.

Labouebe G, Lomazzi M, Cruz HG, Creton C, Lujan R, Li M, Yanagawa Y, Obata K, Watanabe M, Wickman K, Boyer SB, Slesinger PA and Luscher C (2007) RGS2 modulates coupling between GABAB receptors and GIRK channels in dopamine neurons of the ventral tegmental area. *Nat Neurosci* **10**:1559-1568.

Liu YL, Shen-Jang FC, Liu CM, Wu JY, Hung SI, Chan HY, Chen JJ, Lin CY, Liu SK, Hsieh MH, Hwang TJ, Ouyang WC, Chen CY, Lin JJ, Chou FH, Chueh CM, Liu WM, Tsuang MM, Faraone SV, Tsuang MT, Chen WJ and Hwu HG (2006) Evaluation of RGS4 as a candidate gene for schizophrenia. *Am J Med Genet B Neuropsychiatr Genet* **141B**:418-420.

Maison SF, Casanova E, Holstein GR, Bettler B and Liberman MC (2009) Loss of GABA(B) receptors in cochlear neurons: Threshold elevation suggests modulation of outer hair cell function by type II afferent fibers. *J Assoc Res Otolaryngol* **10**:50-63.

Margeta-Mitrovic M, Mitrovic I, Riley RC, Jan LY and Basbaum AI (1999) Immunohistochemical localization of GABA(B) receptors in the rat central nervous system. *J Comp Neurol* **405**:299-321.

Muma NA, Mariyappa R, Williams K and Lee JM (2003) Differences in regional and subcellular localization of G(q/11) and RGS4 protein levels in Alzheimer's disease: correlation with muscarinic M1 receptor binding parameters. *Synapse* **47**:58-65.

Musumeci SA, Bosco P, Calabrese G, Bakker C, De Sarro GB, Elia M, Ferri R and Oostra BA (2000) Audiogenic seizures susceptibility in transgenic mice with fragile X syndrome. *Epilepsia* **41**:19-23.

Musumeci SA, Calabrese G, Bonaccorso CM, D'Antoni S, Brouwer JR, Bakker CE, Elia M, Ferri R, Nelson DL, Oostra BA and Catania MV (2007) Audiogenic seizure susceptibility is reduced in fragile X knockout mice after introduction of FMR1 transgenes. *Exp Neurol* **203**:233-240.

Nomoto S, Adachi K, Yang LX, Hirata Y, Muraguchi S and Kiuchi K (1997) Distribution of RGS4 mRNA in mouse brain shown by in situ hybridization. *Biochem Biophys Res Commun* **241**:281-287.

O'donnell WT and Warren ST (2002) A decade of molecular studies of fragile X syndrome. *Annu Rev Neurosci* **25**:315-338.

Olpe HR, Steinmann MW, Ferrat T, Pozza MF, Greiner K, Brugger F, Froestl W, Mickel SJ and Bittiger H (1993) The actions of orally active GABAB receptor antagonists on GABAergic transmission in vivo and in vitro. *Eur J Pharmacol* **233**:179-186.

Riddle EL, Schwartzman RA, Bond M and Insel PA (2005) Multi-tasking RGS proteins in the heart: the next therapeutic target? *Circ Res* **96**:401-411.

Romano C, Sesma MA, McDonald CT, O'Malley K, Van den Pol AN and Olney JW (1995) Distribution of metabotropic glutamate receptor mGluR5 immunoreactivity in rat brain. *J Comp Neurol* **355**:455-469.

Ross KC and Coleman JR (2000) Developmental and genetic audiogenic seizure models: behavior and biological substrates. *Neurosci Biobehav Rev* **24**:639-653.

Saugstad JA, Marino MJ, Folk JA, Hepler JR and Conn PJ (1998) RGS4 inhibits signaling by group I metabotropic glutamate receptors. *J Neurosci* **18**:905-913.

Schwarz DW, Tennigkeit F and Puil E (2000) Metabotropic transmitter actions in auditory thalamus. *Acta Otolaryngol* **120**:251-254.

Tervonen T, Akerman K, Oostra BA and Castren M (2005) Rgs4 mRNA expression is decreased in the brain of Fmr1 knockout mouse. *Brain Res Mol Brain Res* **133**:162-165.

Ulrich D and Bettler B (2007) GABA(B) receptors: synaptic functions and mechanisms of diversity. *Curr Opin Neurobiol* **17**:298-303.

Volk LJ, Pfeiffer BE, Gibson JR and Huber KM (2007) Multiple Gq-coupled receptors converge on a common protein synthesis-dependent long-term depression that is affected in fragile X syndrome mental retardation. *J Neurosci* **27**:11624-11634.

Wang H, Wu LJ, Kim SS, Lee FJ, Gong B, Toyoda H, Ren M, Shang YZ, Xu H, Liu F, Zhao MG and Zhuo M (2008) FMRP acts as a key messenger for dopamine modulation in the forebrain. *Neuron* **59**:634-647.

Wisniewski KE, Segan SM, Miezejeski CM, Sersen EA and Rudelli RD (1991) The Fra(X) syndrome: neurological, electrophysiological, and neuropathological abnormalities. *Am J Med Genet* **38**:476-480.

Yan QJ, Asafo-Adjei PK, Arnold HM, Brown RE and Bauchwitz RP (2004) A phenotypic and molecular characterization of the fmr1-tm1Cgr fragile X mouse. *Genes Brain Behav* **3**:337-359.

Yan QJ, Rammal M, Tranfaglia M and Bauchwitz RP (2005) Suppression of two major Fragile X Syndrome mouse model phenotypes by the mGluR5 antagonist MPEP. *Neuropharmacology* **49**:1053-1066.

Molecular Pharmacology Fast Forward. Published on April 7, 2009 as DOI: 10.1124/mol.109.056127
This article has not been copyedited and formatted. The final version may differ from this version.

Footnotes

This work was supported by the Fragile X Research Foundation of Canada and the Canadian Institutes for Health Research [MOP-81179].

Reprints: Dr. David R. Hampson
Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, Ontario, Canada M5S 3M2

Molecular Pharmacology Fast Forward. Published on April 7, 2009 as DOI: 10.1124/mol.109.056127
This article has not been copyedited and formatted. The final version may differ from this version.

Figure legends

Fig. 1. FMR1/RGS4 double knockout mice do not express FMRP or RGS4. In A and B, genotyping for FMR1 and RGS4 was carried out using PCR with primers specific to the wild-type and knockout alleles of each gene. In panel A, bands at 534 and 800bp indicate the presence of the FMR1 wild-type and knockout alleles respectively. B, bands at 226 and 484bp indicate the RGS4 wild-type and knockout alleles respectively. C, western blot analysis using an anti-FMRP antibody demonstrating expression of FMRP (~80kDa) in the forebrain of wild-type, but not FMR1/RGS4 double knockout mice. D, RT-PCR analysis demonstrates absence of RGS4 mRNA expression (446bp band) in the forebrain of FMR1/RGS4 double knockout mice. (WT = wild-type; Het = heterozygote; KO = knockout; dKO = FMR1/RGS4 double knockout).

Fig. 2. RGS4 knockout reduces audiogenic seizures in the FMR1 knockout strain. Mice were tested for audiogenic seizures at postnatal day 27-30. A, FMR1 knockout mice were more susceptible to audiogenic seizures than wild-type animals (***$p < 0.001$). FMR1/RGS4 double knockout mice showed a statistically significant reduction in audiogenic seizures as compared to FMR1 knockout mice (**$p < 0.01$). The incidence of seizure activity in double knockout mice was not significantly different from that of wild-type ($p > 0.05$). B, Male FMR1/RGS4 double knockout mice showed a statistically significant decrease in seizure activity as compared to male FMR1 knockouts (**$p < 0.01$). C, Female FMR1/RGS4 double knockout mice showed a trend towards reduced susceptibility to audiogenic seizures compared to FMR1 knockout females; however, this reduction did not reach statistical significance ($p > 0.05$).

Fig. 3. Baclofen blocks seizures in FMR1 knockout mice. 27-30 day old mice were treated with 1 mg/kg or 2 mg/kg R-baclofen. Baclofen significantly reduced audiogenic seizure incidence in FMR1 mice as compared to vehicle controls (* $p < 0.05$; **$p < 0.01$).

Molecular Pharmacology Fast Forward. Published on April 7, 2009 as DOI: 10.1124/mol.109.056127
This article has not been copyedited and formatted. The final version may differ from this version.

Fig. 4. The $GABA_B$ antagonist CGP 46381 induces audiogenic seizures in FMR1/RGS4 double knockout but not wild-type mice. Male wild-type, RGS4 knockout and FMR1/RGS4 double knockout mice were tested for seizure susceptibility at postnatal day 27-30. Treatment with 60 mg/kg of the $GABA_B$ antagonist CGP 46381 resulted in a significant increase in seizures in RGS4 double knockout males (*$p < 0.05$). No seizure activity was observed in wild-type or RGS4 knockout animals with or without drug treatment.

Fig. 5. Co-treatment with an mGluR5 positive modulator and a $GABA_B$ antagonist induces seizures in wild-type mice. Treatment with 2.5 mg/kg of the mGluR5 positive allosteric modulator CDPPB or 60 mg/kg of the $GABA_B$ antagonist CGP 46381 alone did not induce seizures in male wild-type mice. However, the combined treatment of 2.5 mg/kg CDPPB with 60 mg/kg CGP 46381 induced seizures in wild-type animals (* $p < 0.05$; **$p < 0.01$).

Fig. 6. Proposed model depicting Group I mGluR and $GABA_B$ receptor signaling in audiogenic seizures. Top panel, in wild-type animals, a balance between Group I mGluR and $GABA_B$ receptor mediated signaling in auditory pathways prevents seizures. Middle panel, in FMR1 knockout mice, mGluR signaling is enhanced, altering the balance in favour of increased auditory signaling and giving rise to seizures. Lower panel, in FMR1/RGS4 double knockout mice, the absence of RGS4 expression enhances $GABA_B$ receptor signaling thus restoring the balance in auditory signaling pathways and reducing or preventing the seizures.

Figure. 1


A
FMR1:
WT
Het
KO
dKO
800
500
200
KO allele
WT allele
B
RGS4:
WT
Het
KO
dKO
800
500
200
KO allele
WT allele
C
82
FMRP
Wild-type
Double knockout
D
Wild-type
Double knockout
500
400
RGS4

Figure. 2


A
Seizure Incidence (%)
70
60
50
40
30
20
10
0
***
**
0
WT/WT
WT/KO
KO/WT
KO/KO
N =
28
11
30
26
Genotype (FMR1/RGS4)
B
Male
Seizure Incidence (%)
***
**
0
0
WT/WT
WT/Het
WT/KO
KO/WT
KO/Het
KO/KO
N =
23
12
4
12
21
15
Genotype (FMR1/RGS4)
C
Female
Seizure Incidence (%)
0
0
0
WT/WT
Het/WT
Het/Het
WT/KO
Het/KO
KO/WT
KO/Het
KO/KO
N =
5
9
17
7
6
18
4
11
Genotype (FMR1/RGS4)

Figure. 3


**
*
100
80
60
40
20
0
Seizure Incidence (%)
Vehicle
1 mg/kg
2 mg/kg
N =
17
17
16

Figure. 4


Seizure Incidence (%)
100
80
60
40
20
0
*
0
0
0
0
Vehicle
CGP46381
Vehicle
CGP46381
Vehicle
CGP46381
N =
4
4
2
4
5
6
WT Male
RGS4 KO Male
Double KO Male

Figure. 5


*
*
**
100
80
60
40
20
0
Seizure Incidence (%)
0
0
0
Vehicle
CGP46381
CDPPB
CGP46381 + CDPPB
N =
5
5
7
8

Figure. 6


Sound
FMRP
-
Group I mGluRs
+
Auditory Signaling Pathways
-
GABA$_B$R
-
RGS4
-
RGS4
Sound
FMRP
+ +
Group I mGluRs
Auditory Signaling Pathways
-
GABA$_B$R
-
RGS4
-
RGS4
Seizure
Sound
FMRP
+ +
Group I mGluRs
Auditory Signaling Pathways
- -
GABA$_B$R
RGS4
RGS4